source
- After 2 patient deaths and cell therapy durability concerns, Artiva cuts 94% of workforceArtiva Biotherapeutics, which had been evaluating cell therapy AlloNK for the treatment of rheumatoid arthritis and other autoimmune diseases, is exploring strategic options that could include diss…BioSpace · 13d ago↗ source
- Roche's KRAS inhibitor divarasib shows strong results in second-line lung cancer trial at ESMORoche presented data from a trial of its KRAS G12C inhibitor divarasib at the European Society for Medical Oncology meeting. The study evaluated divarasib in patients with advanced non-small cell…